Endotherapeutics is thrilled to announce our latest partnership with Inbody, a worldwide leader in body composition technology. As a trusted distributor of cutting-edge medical technologies, Endotherapeutics will now distribute the InBody 970 and BWA 2.0 in the fields of bariatrics, medical rehabilitation, and medical aesthetics, offering healthcare professionals with the most advanced tools to optimise patient care.
The Inbody 970 sets a new standard in body composition analysis, offering precise measurements that empower healthcare providers in their assessment and treatment of patients. With its advanced bioimpedance technology and user-friendly interface, the Inbody 970 enables practitioners to obtain comprehensive insights into a patient’s body composition, including muscle mass, fat mass, and fluid distribution. This invaluable information facilitates tailored treatment plans and enables more effective monitoring of patient progress over time.
Also available is the BWA 2.0. This state-of-the-art device also harnesses the power of bioimpedance technology to provide accurate and detailed analyses of body water composition. By precisely measuring parameters such as extracellular water, intracellular water, and total body water, the BWA 2.0 equips healthcare professionals with essential data for optimizing hydration status, monitoring fluid balance, and enhancing patient outcomes.
Through our partnership with Inbody, Endotherapeutics strengthens its position as a leading distributor of innovative medical solutions. We are committed to providing healthcare professionals with the tools they need to deliver exceptional care and achieve patient outcomes.
